RCT: Baricitinib vs. dexamethasone for adults hospitalized with COVID-19.

Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial – The Lancet Respiratory Medicine

Commentary on Twitter

?Just Out
ACTT-4 Trial?First Double Placebo-Controlled Double-Blind Randomized-Stratified Head-to-Head#DEXAMETHASONE vs #BARICITINIB for hospitalized pts w/#COVID19 Low/High-Flow/NIV
Relevant?Patient Care/Public Health/Guidelines
Our results
?https://t.co/4Tmue7HK7V
?1/4 pic.twitter.com/aF1Y7BAdu3

— Andre Kalil, MD MPH (@DrAndreKalil) May 24, 2022